Imetelstat in the Lymphoma Landscape

[kmall]

The Pre-Clinical Lymphoid Malignancy study of Imetelstat at the MD Anderson Cancer Center..........

https://ashpublications.org/blood/artic ... chresult=1

"In the lymphoma landscape, telomerase may be a therapeutic target for ABC-type DLBCL (diffuse large B-cell lymphoma); the novel telomerase inhibitor Imetelstat may present one of the potential treatment options."

*Will this study present the opportunity for a Phase 1 Clinical Trial of Imetelstat in Non Hodgkin Lymphoma (NHL)?

It certainly looks promising..........


"Although there are more than 60 types of NHL, diffuse large B cell lymphoma (DLBCL) is the most common type, making up about 30 percent of all lymphomas. In the United States, DLBCL affects about 7 out of 100,000 people each year. DLBCL is a fast-growing, aggressive form of NHL. - Nov 2, 2022"

"DLBCL is a fast-growing, aggressive form of NHL. DLBCL is fatal if left untreated, but with timely and appropriate treatment, approximately two-thirds of all people can be cured."

https://www.uptodate.com/contents/diffu ... -basics#H1

**Imetelstat being able to target DLBCL patients, would greatly benefit Geron in their efforts to garner market share in the Hematological Disorders space. NHL is by far one of, if not the largest patient populations Geron/Imetelstat could treat. It translates to approximately 560,000* patients/yr globally. (*2022) -Kmall

[kmall]

Global patterns of non-Hodgkin lymphoma in 2020....

https://onlinelibrary.wiley.com/doi/abs ... /ijc.34163



US 2022 patient population estimates......

https://www.google.com/amp/s/amp.cancer ... stics.html



Global Non-Hodgkin Lymphoma Therapeutics Market Report 2021: Market to Reach $8.1 Billion by 2027

https://www.businesswire.com/news/home/ ... arkets.com